SCHOTT Pharma AG & Co. KGaA
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG01JFK07F4
1SXP
SCHOTT Pharma AG & Co. KGaA
GICS: -
·
Sector: -
·
Sub-Sector: -
NAME
SCHOTT Pharma AG & Co. KGaA
ISIN
DE000A3ENQ51
TICKER
1SXP
MIC
XETR
REUTERS
1SXP.DE
BLOOMBERG
1SXP GR
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
EQS Newswire is a major provider of regulatory and corporate news. It mainly serves companies, investors and media worldwide. Through its services, EQS Newswire enables efficient and secure communication between companies and their stakeholders. Its main services include the distribution of ad hoc announcements, corporate news and the publication of financial reports that meet strict international standards.
Thu, 26.09.2024
SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU”
Market advances adoption of ready-to-use containers
Improved operational efficiency in pharmaceutical manufacturing processes
Increased patient safety with high-quality sterile primary packaging
SCHOTT Pharma AG & Co. KGaA (MDAX: 1SXP), a pioneer ...
Thu, 05.09.2024
Promotion for SCHOTT Pharma: Listed on the MDAX for the first time
SCHOTT Pharma to join the 90 most important shares listed on the Frankfurt stock exchange as of September 23, 2024
MDAX promotion proves confidence in the company’s business model, strategic focus and ideal market position
The shares of SCHOTT Pharma AG & Co. KGaA, a global...
Thu, 29.08.2024
SCHOTT Pharma delivers strong third quarter results and raises FY 2024 revenue guidance
Q3 2024 revenues up 21% yoy to EUR 268m at constant currencies
Strong Q3 2024 EBITDA margin of 28.2% at constant currencies
Share of strong-margin high-value solutions (HVS) at 53% in the first nine month of FY 2024
SCHOTT Pharma increases revenue guidance ...
Thu, 08.08.2024
SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement
August 8, 2024, Germany, Mainz
SCHOTT Pharma is fully committed to take responsibility for emission reduction to support limitation of global warming to 1.5°C.
The independent Science Based Targets initiative (SBTi) has validated the clima...
Wed, 31.07.2024
Transforming operational efficiency and sustainability: SCHOTT Pharma introduces nest design with more cavities for prefillable polymer syringes
31 July 2024, Germany, Mainz
SCHOTT Pharma’s new nest holds 160 prefillable polymer syringes, which marks an increase of 60 syringes per nest.
The new nest design allows pharma companies to increase the...
Tue, 16.07.2024
Driving subcutaneous self-injection of large volume doses: SCHOTT Pharma launches large format ready-to-use cartridges for on-body devices
16 July 2024, Germany, Mainz
SCHOTT Pharma introduces new 10ml ready-to-use (RTU) cartridges, specifically designed to store highly sensitive biologics used to treat cancer, metabolic disorders, cardiovascular...
Thu, 27.06.2024
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024
Q2 2024 revenues up 11% yoy to EUR 247m at constant currencies
Q2 2024 EBITDA margin of 27.0% at constant currencies
Share of strong-margin high-value solutions (HVS) at 53% in the first half of FY 2024
Guidance for fiscal year 2024 confirmed
SCHOTT Pharma, a pioneer ...
Thu, 27.06.2024
SCHOTT Pharma continues growth path in the second quarter of fiscal year 2024
Q2 2024 revenues up 11% yoy to EUR 247m at constant currencies
Q2 2024 EBITDA margin of 27.0% at constant currencies
Share of strong-margin high-value solutions (HVS) at 53% in the first half of FY 2024
Guidance for fiscal year 2024 confirmed
SCHOTT Pharma, a pioneer ...
Fri, 14.06.2024
Expanding prefillable glass syringe output: SCHOTT Pharma opens state-of-the-art production facility in Lukácsháza, Hungary
June 11, 2024, Lukácsháza, Hungary
After EUR 76 million (HUF 28,044 billion) investment and 1.5 years of construction, SCHOTT Pharma opens its newest production facility in Lukácsháza, Hungary
Expanding production capacity ...
Tue, 14.05.2024
SCHOTT Pharma confirms outlook for FY 24 based on Q2 results; FY 25 impacted by slower growth from syringes
H1 24 revenues up 9% yoy at constant currencies to EUR 489m; EBITDA margin of 27.4% at constant currencies
FY 25 revenue growth projections impacted by lower demand for syringes from one customer
Mid-term outlook confirmed
Full set of Q2...
Information on product placements
